Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HLCS | P50747 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12802812 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL135862 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL131691 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL131798 | 1.00 | — | — | |
| SCHEMBL128977 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL130922 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12802854 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL130492 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL330174 | 1.00 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL130670 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3059235-B1 | TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS | SUMITOMO CHEMICAL CO (JP) | 2020-10-28 | — | — | EP | disclosed |
| US-10085450-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-20160270399-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059235-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| EP-1756271-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2015-12-09 | — | — | EP | disclosed |
| EP-1753862-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES | CSIR (ZA) | 2015-11-18 | — | — | EP | disclosed |
| US-9029069-B2 | Resist underlayer film-forming composition and method for forming pattern | JSR CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085450-B2 | Tetrazolinone compound and use thereof | ROS1, TCOF1, RPS20 | MAPT 3692/4885CYP1A2 309/4885CYP2D6 369/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | MAPT 2435/4885CYP1A2 1483/4885CYP2D6 3128/4885 |
| US-20160270399-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | ROS1, TCOF1, RPS20 | MAPT 3692/4885CYP1A2 309/4885CYP2D6 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.